{"nctId":"NCT00230178","briefTitle":"Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome","startDateStruct":{"date":"2004-04"},"conditions":["Tumor Lysis Syndrome","Cancer","Hyperuricemia"],"count":280,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Rasburicase (SR29142)"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Rasburicase (SR29142)","Drug: Allopurinol"]},{"label":"Arm C","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Allopurinol"]}],"interventions":[{"name":"Rasburicase (SR29142)","otherNames":[]},{"name":"Allopurinol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Meets high risk or at potential risk for tumor lysis syndrome (TLS):\n\n   A patient is at high risk for TLS if he/she presents with:\n   * Hyperuricemia of malignancy (plasma uric acid \\> 7.5 mg/dL);\n   * A diagnosis of very aggressive lymphoma/leukemia based on the Revised European-American Lymphoma (REAL) classification of lymphoma/leukemia;\n   * Acute myeloid leukemia (AML);\n   * Chronic myeloid leukemia (CML) in blast crisis; or\n   * High grade myelodysplastic syndrome (refractory anemia with excess blast, chronic myelomonocytic leukemia, and refractory anemia with excess blast in transformation) only if they have \\> 10% bone marrow blast involvement and are given aggressive treatment similar to AML.\n\n   A patient is at potential risk for TLS if he/she presents with:\n   * A diagnosis of aggressive lymphoma/leukemia based on the REAL classification of lymphoma/leukemia plus 1 or more of the following criteria:\n\n     * Lactate dehydrogenase (LDH) \\>= 2 x upper limit of normal (ULN) (IU/L)\n     * Stage III-IV disease\n     * Stage I-II disease with at least 1 lymph node/tumor \\> 5 cm in diameter\n\n   In addition to the above-mentioned eligibility criteria, the patients should have the following criteria:\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n3. Age \\>= 18 years\n4. Life expectancy \\> 3 months\n5. Negative pregnancy test (females of child bearing potential) and use of effective contraceptive method (for both males and females). A pregnancy test may be performed on serum or urine human chorionic gonadotropin (HCG).\n6. Signed written informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Plasma Uric Acid Responder","description":"Number of patients responding to treatment defined as plasma uric acid levels at Day 3 through Day 7 \\<7.5 mg/dl.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Uric Acid","description":"Area under the curve concentration versus time curve extrapolated to infinity (AUC) of plasma uric acid values","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.25","spread":"57.17"},{"groupId":"OG001","value":"108.05","spread":"70.49"},{"groupId":"OG002","value":"646.22","spread":"285.29"}]}]}]},{"type":"SECONDARY","title":"Time to Uric Acid Control","description":"Time from the first dose of study drug to the time at which plasma uric acid concentrations were determined \\<=7.5 mg/dl, measured -4, 4, 24, 48, 72, 96, 120, and 144 hours after infusion.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.1","spread":null},{"groupId":"OG002","value":"27.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":92},"commonTop":["Nausea","Diarrhoea","Pyrexia","Thrombocytopenia","Neutropenia"]}}}